StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Investment analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Price Performance

NASDAQ:TXMD opened at $1.18 on Friday. TherapeuticsMD has a 12-month low of $1.15 and a 12-month high of $2.75. The firm has a 50-day moving average price of $1.45 and a 200 day moving average price of $1.67.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.